Longboard Pharmaceuticals

Longboard Pharmaceuticals : Focused on developing a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. The company is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
4275 Executive Square
Suite 950
La Jolla, CA 92037
United States

Company Participants at Solebury 1x1 Management Access Event 2023

  • Kevin Lind, President and CEO

Top 10 Holders of Longboard Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 12.50 2,567,948 14.28 13F 6/30/23
Cormorant Asset Management LP 11.45 2,353,141 13.08 13F 6/30/23
T Rowe Price Associates, Inc. (13F Subfiler) 8.22 1,688,156 9.39 13F 6/30/23
T. Rowe Price Associates, Inc. (Investment Management) 7.26 1,492,777 8.30 Funds 6/30/23
Fidelity Investments Canada ULC 6.94 1,427,422 7.94 Funds 7/31/23
HBM Partners AG (Investment Management) 9.90 1,345,009 7.48 Stakes 12/31/22
Farallon Capital Management LLC 4.87 1,000,000 5.56 13F 6/30/23
Point72 Asset Management LP 4.01 825,000 4.59 13F 6/30/23
Prosight Management LP 3.58 734,897 4.09 13F 6/30/23
Vanguard Group, Inc. (Subfiler) 3.16 650,052 3.61 13F 6/30/23

Top 10 Holders of Longboard Pharmaceuticals, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Cormorant Asset Management LP 22.65 822,164 0.00 Stakes 12/31/22
Farallon Capital Management LLC 16.74 607,417 0.00 Stakes 12/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.